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DLL1: Delta-like protein 1
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mRNA: messenger RNA
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7Abstract
Medulloblastoma (MB) is a highly aggressive cancer that mostly affects children, through
developmental impairment of the cerebellum. Several miR34a targets belong to the Notch
pathway, a signaling pathway that is involved in cerebellum development and that is
aberrantly activated during MB tumorigenesis. We show here that miR34a over-expression
transiently down-regulates the Notch ligand Delta-like 1 (DLL1) protein levels and also
results in Notch1 activation and Notch2 signaling inhibition, an effect that we see in the
MB Daoy and D283-MED cells. Moreover, ectopic expression of miR34a in MB cells
results in impairment of proliferation rate and soft agar colony formation, while inducing
apoptosis and differentiation processes. Noteworthy, the induction of apoptosis was
inhibited by ectopic expression of DLL1, suggesting the involvement of DLL1 down-
regulation in this process. We also provide evidences that the endogenous expression of
miR34a can down-regulate DLL1 protein levels and contribute to the p53-induced
apoptosis in Daoy cells, upon doxorubicin stimulation. Induction of miR34a correlates
with DLL1 protein down-regulation also in neuroblastoma and breast cancer cells and
expression of miR34b and miR34c can contribute to the DLL1 down-regulation.  Finally,
we report that miR34a, miR34b and miR34c, are down-regulated in human MB tumors.
These results suggest that miR34a has an onco-suppressor function in MB and that it can
thus be targeted for future therapeutic applications.
8INTRODUCTION
Medulloblastoma
Medulloblastoma (MB) a highly invasive embryonal tumor of the cerebellum. It is the
most common malignant brain tumor in children and accounts for more than 25% of
childhood cancer-related deaths (Wang et al., 2008)
MB occurs bimodally, with peaks of incidences between 3 and 4 years and 8 and 9 years of
age, even if can also arise in adults, showing the highest incidence at 20-34 years of age
(Crawford et al., 2007). Patients with MB generally show symptoms of obstruction of
cerebrospinal fluid flow and cerebellar disfunction including macrocephaly, vomiting and
ataxia (Crawford et al., 2007).
MB is currently classified in several variants: classic, desmoplastic, anaplastic, large-cell
MB and the MB with extensive nodularity (Gilbertson & Ellison, 2008).
Classic tumors are composed of small round or ellipsoid cells with a high nuclear-to-
cytoplasmic ratio, showing scant cytoplasm and dense hyperchromatic nuclei.
The desmoplastic variant is composed of highly proliferative, densely packed and reticulin
reach areas that surround reticulin-free nodules. This variant represents 50% of adult cases
of MB and 15% of children related cancer.
Desmoplastic medulloblastomas encompass the nodular/desmoplastic MB and the
medulloblastoma with extensive nodularity, which contribute approximately 7% and 3% of
all medulloblastomas, respectively.
Since all large-cell medulloblastomas have regions of anaplasia, anaplastic and large-cell
tumors, accounting for almost 10%-22% and 2%-4% of all medulloblastomas,
respectively, are often grouped as large-cell/anaplastic (LCA) medulloblatomas, which
represents the most malignant variant (Gilbertson & Ellison, 2008).
9Most medulloblastomas are confined to the posterior fossa, however all of the variants can
metastasize and 11-43% of patients show disseminated disease either along the
craniospinal axis, or, more rarely, to extraneural sites (Crawford et al., 2007).
Disease dissemination rate, patient age and post-operative residual mass represent the most
important prognostic markers for MB tumors.
MB patients are indeed divided into risk-stratification groups with patients older than 3
years and gross or near-total surgical tumor resection assigned to the average-risk category,
which accounts for 60%-70% of all MB patients; and patients with disseminated disease at
presentation or greater than 1.5 cm2 of residual tumor mass identified as high-risk
category. A third stratification scheme is used for patients younger than 3 years old, who
generally have worse outcomes mostly due to the increased risk of metastatic disease at
presentation, increased rate of subtotal resection, and not receiving craniospinal radiation
therapy (Crawford et al., 2007).
Risk-adapted treatments are currently adopted in the management of the MB, including
surgical tumor resection, radiotherapy and chemotherapy.
Surgery represents the first approach and a fundamental part of MB treatment. It’s aimed
to the maximal tumor resection and has shown clear effects of survival improvement,
particularly in patients with localized disease (Rutkowski et al., 2005).
Addition of radiation therapy to the surgery, has allowed an overall improvement of MB
patients survival. However, craniospinal axis irradiation often results in severe deleterious
effects, particularly in infants, thus it is delayed or not given to children younger than 3
years (Crawford et al., 2007).
MB patients belonging to all risk-groups are also commonly treated with chemotherapeutic
drugs, including vincristine, cyclophosphamide, etoposide and methotrexate. For younger
patients, chemotherapy is widely used as the initial treatment, aimed to delay or avoid
radiation therapy. Indeed, intensive postoperative chemotherapy alone showed promising
results for treatment of young children without initial metastases (Rutkowski et al., 2005).
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Other therapeutic approaches include the use of myeloablative doses of chemotherapy
followed by autologous stem cell rescue. Early studies have reported a survival
improvement for patients with high-risk medulloblastoma; however, 15% of patients died
of treatment-related toxicity (Perez-Martinez et al., 2005).
Relapse of MB generally manifest within 2 years from the initial therapy in infant, and
upon 5 years in adults. The management of patients with relapsing disease varies and
depends on a range of factors including the age of the patient and the dissemination rate of
the disease. However, surgery and possible combined use of chemotherapy and
radiotherapy represent the leading therapeutic approach (Crawford et al., 2007).
The employment of multimodality treatment regimens has significantly improved survival
rates for MB. However, although patients belonging to the average-risk category show an
overall survival rate approaching 70% to 80%, the high-risk patients are generally
associated to a very poor prognosis, and MB results still incurable for more then one third
of patients. Moreover, survivors commonly suffer of severe long-term side effects due to
the aggressive treatments (Crawford et al., 2007; Gilbertson & Ellison, 2008).
Neurocognitive defects are one of the most pervasive of all long-term effects and occur
across all age groups. Despite receiving reduced doses of intracranial radiation, younger
patients generally have a worse outcome and can show significant declines in intelligence
quotient (IQ), correlated with the total dose of radiotherapy and the patient age (Perez-
Martinez et al., 2005). The possibility to develop endocrinopathies and secondary
malignancies, including high-grade brainstem gliomas, cerebral gliomas, and meningiomas
is also a long-term concern for patients treated with radiation therapy (Crawford et al.,
2007).
Surgery may also be associated with temporary or permanent neurologic worsening due to
postoperative infection and direct brain or cerebellar damage. Moreover, nearly 25% of
patients show symptoms of the postoperative cerebellar mutism syndrome. This syndrome
of delayed onset, typically hours after surgery, presents with mutism, and can persist for
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days or months. The etiology of posterior fossa mutism is still unclear (Crawford et al.,
2007).
The tumor’s cell of origin and the cellular pathways active in MB tumorigenesis are
believed to play a crucial role in the prognosis and possibly response to therapy of MB (de
Bont et al., 2008).
Therefore, a better understanding of the pathology and molecular biology of
medulloblastoma tumorigenesis is necessary, to identify more efficient therapeutic
approaches, thereby improving survival and quality of life of MB patients.
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Pathogenesis of MB
The origins of MB are intimately related to the cerebellum development. Indeed, although
the precise tumor initiating cells are still to be defined, MB can originate from progenitor
cells and neuronal stem cells of the cerebellum (Yang et al., 2008), and pathways
regulating the normal cerebellum development play a crucial role in the MB tumorigenesis
(Marino, 2005).
Three distinct germinal zones are involved in cerebellum development: the ventricular
zone (VZ), the rombic lip (RL) and the white matter (Lee et al., 2005; Wang & Zoghbi,
2001).
Most of the cerebellum cell types, including Purkinjie cells and neurons, such as stellate,
basket and Golgi interneurons, generate from multipotent neuronal stem cells (NSCs) of
the ventricular zone (VZ); on the other hand cerebellar granule neurons, the most abundant
neurons of the brain, develop from a second germinal zone, known as the rhombic lip
(Wang & Zoghbi, 2001).
During embryonic development, granule neuron precursor cells (GNPs) of the rombic lip
proliferate and migrate over the surface of the cerebellum, generating the external granular
layer (EGL). GNPs then migrate inward and differentiate into granule neurons, which form
the internal granular layer (IGL) (see Fig.1). The EGL persists until postnatal day (P) 15 in
the mouse and into the second postnatal year in the human (Lee et al., 2005). A third stem
cell population has been isolated from the white matter of the postnatal cerebellum. These
cells can give rise to astrocytes, oligodendrocytes and neurons, but not granule cell neurons
(Lee et al., 2005).
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Figure 1. Schematic representation of cerebellar development. (a), (b)
Embryonal development. Progenitor cells located in the ventricular zone (VZ, primary
genrminal zone) migrate radially to give rise to Purkinje cells. Progenitor cells located in
the rhombic lip (RL) migrate dorsally to populate the external granular layer (EGL,
secondary germinal zone). (c) Postnatal development. Progenitor cells located in the EGL
clonally expand, become postmitotic, differentiate and migrate inwards to generate the
internal granular layer (IGL). Golgi, basket and stellate neurons are originating from the
neuroepithelium (NE) of the ventricular zone. The site of origin of medulloblastoma (EGL
and NE) is shown on the right-hand side. From  (Marino, 2005)
Emerging evidences indicate that MB tumors can generate from either GNPs or NSCs,
upon activation of the Sonic Hedgehog (Shh) signaling (Yang et al., 2008).
Shh, Wnt and Notch signaling regulate cerebellum development, and several genes
belonging to these pathways are frequently mutated or deregulated in human MBs (see
table 1).
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Table 1. Genes frequently mutated or deregulated in human MB tumors.
The most common MB-associated genetic lesion is the loss of chromosome 17p region,
associated to deletion or deregulation of the indicated genes. Several genes belonging to
the Shh, Wnt and Notch pathway are frequently deregulated or mutated in MB tumors. Of
note: Notch1 was undetectable in 40% of cases whereas Notch2 reported overexpressed
and amplified; OTX2 was reported overexpressed in 90% of anaplastic MBs; PDGFRα
overexpression reported 83% only in metastatic cases, no overexpression was detected in
non-metastatic (adapted from Ferretti e et al. 2005).
Expression deregulation of several other genes has been also reported in MBs: for example
MYCC overexpression is observed in 30% to 50% of tumors and often associated to
anaplasia (Stearns et al., 2006). Similarly, expression of the tyrosine kinase receptor
ERBB2 has been demonstrated in 40% of MB and more frequently in LCA variants
(Gajjar et al., 2004); and the OTX2 transcription factor and the Insulin growth factor
receptor-1 (IGF-1R) protein are also over-expressed in most MBs (de Bont et al., 2008; de
Haas et al., 2006).
15
Comparative genomic hybridization (CGH) analyses identified several chromosomal
aberrations in medulloblastomas: the most common is loss of the chromosome 17p region,
frequently associated with a gain of chromosome 17q, leading to an isochromosome 17q.
Both loss of 17p and gain of 17q are prognostically unfavorable factors (Ferretti et al.,
2005). Amplification of the MYCC oncogene has been also reported in approximately 5%
to 10 % of medulloblastomas and mostly associated with the LCA variant (Eberhart et al.,
2004).
The signaling pathways involved in MB tumorigenesis have been also demonstrated, in
same cases, attractive therapeutic targets. Indeed, Notch signaling blockade by using
pharmacologic inhibitors of gamma secretase, caused induction of differentiation and
apoptosis in MB cells, also impairing soft agar colony formation and xenograft tumor
growth (Fan et al., 2006; Fan et al., 2004). Similarly, pharmacologic inhibition of the Shh
pathway blocked proliferation and induced neuronal differentiation and cell death in MB
cells (Berman et al., 2002). Moreover, administration of Shh antagonists was reported to
eliminate tumor growth in a mouse model of spontaneous medulloblastoma (Romer et al.,
2004).
Emerging evidences indicated that a class of small non-coding RNA, microRNAs
(miRNAs) is also involved in MB tumorigenesis.
miRNA expression profiling showed that many of them are aberrantly expressed in
primary human MBs tumors (Ferretti et al., 2009), and remarkably, expression of miRNAs
that specifically target the Shh or Notch pathways, recapitulated the biological effects
mediated by pharmacological inhibition of these signaling (Ferretti et al., 2008; Garzia et
al., 2009).
Indeed, we have recently described an oncosuppressor miRNA (miR199b-5p), which
targets the Hes1 gene, a key effector of the Notch pathway, and inhibits survival of MB
cells also impairing MB cancer stem cell population (Garzia et al., 2009).
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Moreover, Ferretti and colleagues described three other miRNAs, miR125b, miR324-5p
and miR326, which impair MB cell growth by targeting the Shh pathway (Ferretti et al.,
2008).
These findings indicate miRNAs as potential new therapeutic tools for MB treatment.
.
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The Sonic Hedgehog (Shh) pathway
The hedgehog signaling, in mammalas, initiates by one of three homologues of the
Drosophila hedgehog protein sonic hedgehog (Shh), indian hedgehog (Ihh) and desert
hedgehog (Dhh). Among the three Hh family members, Shh is the most broadly expressed
and is involved in the patterning and growth of a large variety of organs, including the
brain, lung, and skeletal system.
Shh signaling regulates multiple aspects of central nervous system (CNS) development,
controlling both cell proliferation and differentiation.
In the developing cerebellum, Purkinje cells secrete Shh, which acts as potent mitogen for
GNPs (Fuccillo et al., 2006).
Shh triggers cellular signals by interacting with the 12-pass transmembrane receptor
Patched (Ptc). This interaction prevents inhibition of 7-pass transmembrane Smoothened
(Smo) co-receptor by Ptc and enables it to activate downstream transcription factors
belonging to the Gli family (Gli1, -2 and –3); these factors translocate into the nucleus and
activate the expression of target genes such as Gli1 and Ptc themselves, but also important
regulators of the cell cycle and apoptosis including N-myc, cMyc, cyclin D1 and D2, Hes1
and Bcl2 gene (Ferretti et al., 2005) (see Fig.2).
Shh signaling was first implicated in MB formation following the discovery of inactivating
PTC1 mutations in the germ line of kindred with the nevoid basal-cell carcinoma
syndrome (NBCCS, also known as Gorlin syndrome). Patients with NBCCS develop
characteristic bone cysts and multiple basal cell carcinomas, and are predisposed to a
variety of other tumor types, including medulloblastomas. In mice, heterozygous mutation
of PTC1 gene is associated with a 15% of incidence of MB over a period of 10 months
(Goodrich et al., 1997). Moreover, the lack of p53 in PTC1 heterozygous mice increases
the incidence of MB to >95% also decreasing the latency over a period of 12 weeks
(Wetmore et al., 2001). These mouse tumors display a very similar gene expression
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signature to those of human PTC1 mutant tumors, both showing induction of Shh target
genes. Among them, Gli1 is an important effector of Hedgehog-induced tumorigenesis, as
inactivation of both Gli1 alleles in PTC1 heterozygous mice significantly reduces MB
formation (Kimura et al., 2005).
Remarkably, suppression of the Shh pathway by using small molecule inhibitors, arrests
MB formation in PTC-/+ as well as PTC-/+ p53-/- mice (Berman et al., 2002; Romer et al.,
2004). For these reasons inhibition of the Shh pathway can be an effective treatment for
MB tumors.
Figure 2. Diagram of the Shh pathway. In the absence of the Shh ligand, Ptc
represses Smo. Signaling is initiated by binding of Shh to Ptc, which relieves the
repression of Smo. Subsequently, Smo signals to the nucleus by increasing the
concentration of Gli transcription factors, which recruit co-activators to activate
downstream target genes. From (Radtke and Ray, 2003)
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The Notch pathway
The Notch pathway is evolutionarily conserved and presents in organisms as diverse as
worm and humans. Humans express four different Notch receptors (Notch1 -4), which are
homologous of the drosophila receptor dNotch, and five drosophila Delta and Serrate
homologues ligands, named Delta-like-protein 1 –3 and –4 (DLL1, DLL3 and DLL4) and
Jagged 1 and Jagged 2 (Jag1 and Jag2) (see Fig.3).
The ligands share several characteristics with the Notch receptors: both are expressed as
transmembrane proteins, with large N-terminal extra-cellular portions consisting of
varying numbers of EGF-like repeats (Fig.1) (Radtke & Raj, 2003).
Figure 3. Structure of Notch receptors and ligands. A. Drosophila has one
Notch receptor (dNotch) and vertebrates have four (Notch1-4), which are presented on the
cell surface as heterodimers. The extracellular domain contains epidermal-growth-factor
(EGF)-like repeats and a cystein-rich Notch/Lin12 domain (LN); this is followed by the
transmembrane domain, the RAM domain and six ankyrin repeats (ANK), two nuclear
localization signals (NLSs), followed by the transactivation domain (TAD) and a PEST
sequence. B. Two transmembrane-bound ligands for Notch have been identified in
Drosophila, named Delta (Dl) and Serrate (Ser). The vertebrates possess three Delta-like
ligands (DLL) –1, -3, 4, and two serrate homologues, Jagged 1 (JAG1) and Jagged 2
(JAG2). The ligands harbour an amino terminal structure called DSL (Delta, Serrate and
LAG-2), which is common to all family members, followed by EGF-like repeats. Serrate,
Jagged1 and Jagged2 harbour a cysteine-rich domain (CR following the EGF-like repeats.
Adapted from (Radtke & Raj, 2003).
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Ligand-receptor interaction take place between two neighboring cells and results in two
successive proteolitic cleavages at the transmembrane portion of the Notch receptor. Two
transmembrane enzymes, the ADAM10 or TACE (TNF-a-converting enzyme)
metalloprotease and the γ-secretase complex, mediate the receptor processing, which
results in the release of the Notch intracellular domain (NICD) from the membrane (see
Fig.4). NICD subsequently enters the nucleus and binds to the transcription factor CSL
(CBF1, Su(H) and LAG1). Through interaction with NICD, CSL is converted from a
repressor into an activator of transcription and induces expression of the Notch target
genes. One of the best-characterized targets is the HES (hairy/enhancer of split) family of
transcription factors, which consists of Hes1, -3 and –5, all negative regulators of gene
expression (Radtke & Raj, 2003).
Figure 4.  The Notch pathway. Binding of the Delta (green) on one cell to the
Notch receptor (purple) on another cell results in two proteolytic cleavages of the
receptor. The ADAM10 or TACE (TNF-α-converting enzyme) metalloprotease (yellow)
catalyses the S2 cleavage, generating a substrate for S3 cleavage by the γ-secretase
complex (brown). This proteolytic processing mediates release of the Notch intracellular
domain (Nicd), which enters the nucleus and interacts with the DNA-binding CSL (CBF1,
Su(H) and LAG-1) protein (orange). The co-activator Mastermind (Mam;green) and other
transcription factors are recruited to CSL complex, whereas co-repressors (Co-R; blue
and grey) are released. From (Bray, 2006).
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Besides activating the Notch receptors via cell-cell interactions, Notch-ligands can cell
autonomously antagonize Notch signaling (Ladi et al., 2005). DLL ligands cell
autonomously bind Notch1 receptor. This complex is not present on the cell surface but
retained in the endoreticulum or Golgi apparatus. DLL-Notch cell autonomous interaction
show a dominant negative effect interfering with the ability of the cell to receive Notch
signal by neighboring cells (Sakamoto et al., 2002).
The Notch pathway is involved in the development of several organs, including the
nervous system. In particular the Notch pathway is required for the correct neuronal and
glial differentiation of the cerebellum, and for the proliferation of GNPs and NSCs (Louvi
& Artavanis-Tsakonas, 2006).
Notch1 and Notch2 receptors have distinct roles in controlling proliferation and
differentiation of GNP cells: Notch2 signaling acts as a mitogen for cerebellar GNPs,
whereas Notch1 receptor is only expressed in differentiated granule neurons and is not
detected in proliferating precursor cells (Fan et al., 2004; Solecki et al., 2001). Differential
expression of Notch1 and Nocth2 receptors was also detected in human MB tumors with
Notch2 over-expressed, and Notch1 mRNA detected at very low levels (Fan et al., 2004).
Also, Hes1 expression is associated with decreased survival rate of MB patients (de Bont
et al., 2008), and interestingly, is induced upon Notch2, but not Notch1 activation, in MB
cells (Fan et al., 2004). In vitro studies indicate that Notch1 and Notch2 receptors have
opposite effects in MB cells: Notch2 activation promotes cell proliferation, soft agar
colony formation and xenograft growth, whereas Notch1 activation induces apoptosis (Fan
et al., 2004). Consistently, MB cells show constitutive activation of Notch2 whereas
Notch1 is inhibited (Fan et al., 2004), therefore Notch signaling blockade, by using γ-
secretase inhibitors, causes cell cycle exit, apoptosis and differentiation in MB cells (Fan et
al., 2006), thus effects only referable to the Notch2 signaling inhibition.
For these reasons the Notch signaling is considered an important therapeutic target for MB
treatment.
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 Small non protein-coding RNAs: microRNA (miRNA)
Biogenesis
MicroRNAs (miRNAs) are small non-coding RNAs able to post-trascriprionally regulate
gene expression through translational inhibition and destabilization of their target mRNAs.
Almost one thousand of human miRNAs have been identified and are predicted to regulate
about one third of human genes (Pillai et al., 2007).
miRNAs map either within interegenic regions, as independent transcription units, or into
introns or exons of protein-encoding genes, coexpressed with the host gene or
independently transcribed via alternative promoters. They can be expressed as single
transcription units or clustered within policistronic transcripts (see Fig.5) (Baskerville &
Bartel, 2005; Rodriguez et al., 2004).
miRNAs are transcribed as very long primary transcripts (pri-miRNAs) by RNA
polymerase II (Lee et al., 2004) or RNA polymerase III (Borchert et al., 2006).
Pri-miRNAs are usually several kilobases in length and, like protein coding mRNAs, are 7-
methyl guanosine capped at the 5’ end, and polyadenylated at the 3’ end (Lee et al., 2004).
Each miRNA sequence folds as imperfect hairpin-like stem loop structures of ≈3 helical
turns. These structures are recognized and processed by a protein complex called
“Microprocessor” consisting of Drosha, an RNAse III enzyme and its cofactor DGCR8
(Lee et al., 2003). Drosha transiently interacts with the stem region of the hairpin and
cleaves the RNA duplex about 11 nt from the double strand region (SD junction) (Han et
al., 2006).
The Drosha-mediated processing of pri-miRNAs occurs co-transcriptionally and generates
70nt precursor miRNAs (pre-miRNA), containing a 2-nt overhang at its 3’ end (Lee et al.,
2003; Morlando et al., 2008).
pre-miRNAs are exported outside the nucleus by the nuclear transport factor exportin-5
(Exp5) (Lund et al., 2004) and, once in the cytoplasm, are processed by the RNase 
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enzyme Dicer, as part of a complex including also TRBP and Argonaute 2 (Ago2) proteins
(see Fig.5) (Diederichs & Haber, 2007). Dicer recognizes the double stranded portion of
the pre-miRNA and cuts both strands of the duplex, at about two helical turns away from
the base of the stem loop. This processing generates an imperfect duplex of 19 nt, and 2-nt
unpaired overhangs at each 3’-end, and a 5’- phosphate on each strand (Standart &
Jackson, 2007).
The duplex is unwound, by a helicase which is still unknown, resulting in the release of
two single-strand RNAs: the mature miRNA, generally selected as the duplex strand with
the thermodynamically less-stable 5’ end, which is loaded into a multi protein complex
known as RNA-induced silencing complex (RISC); and the mature miRNA-
complementary strand, known as miRNA “star” (miRNA *), which is rapidly degraded
(Bartel, 2004; Khvorova et al., 2003).
The mature miRNA-RISC ribonucleoprotein complex can then regulates the expression of
miRNA target genes by inducing mRNA degradation or translational repression, through
different proposed mechanisms (see Fig.5).
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Figure 5. miRNA biogenesis.  Single or clustered miRNAs are transcribed as pri-
miRNAs and fold as hairpin-like structures. Drosha cleavage generates a precursor
miRNA (pre-miRNA) which is exported outside the nucleus by the nuclear factor exportin-
5. Dicer processes pre-miRNAs within the cytoplasm and generates the 21-nt duplex,
which contains the mature miRNA sequence. The RISC complex loads the mature miRNA
and, upon miRNA/mRNA pairing, regulates target mRNA expression by inducing mRNA
degradation or translation inhibition. From (Chang-Zheng C., 2005).
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Mechanisms of action of miRNAs
The last step of miRNA maturation results in the formation of the 21nt-mature miRNA,
which is loaded within the RISC complex.
RISC is a multi protein complex consisting of several subunits including Argonaute (Ago)
proteins and GW182, an RNA binding protein. Ago proteins are a large family of 95 Kda
proteins consisting, in mammals, of four members (Ago1 to Ago4) that directly bind
miRNAs. Among them, Ago2 has Rnase H enzymatic activity (Filipowicz et al., 2008).
miRNAs pair complementary sites (miRNA binding sites) within the mRNA target
sequences, allowing the RISC complex to be loaded on the target mRNA.
Target recognition represents an important step for miRNA functions, as it confers
selectivity and efficacy of action.
In most reported cases animal miRNAs pair through imperfect complementarity with their
binding sites residing within the 3’UTRs (3’ untraslated regions) of target mRNAs.
However emerging evidences demonstrated that 5’ UTRs and open reading frames (ORFs)
of several genes can contain miRNA-binding sites and thereby can be recipients of the
miRNAs activity (Lytle et al., 2007; Tay et al., 2008).
Several features of both miRNA and mRNA sequences determine the specificity and the
efficacy of the binding.
1) Perfect pairing between the miRNA seed region (2-7 nt of the 5’ end) and miRNA
binding site within the target 3’UTR revealed in some cases sufficient for target
downregulation (Brennecke et al., 2005). However, seed sites do not always confer
repression, and when repression occurs, the degree of repression is highly variable
in different UTR contexts. Supplemental pairing outside of the seed region,
particularly to nucleotides 13-16 of the miRNA, can indeed increase the repression
efficiency (see Fig.6) (Grimson et al., 2007).
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2) Multiple miRNA binding sites within the same 3’UTR have shown multiplicative
effects in mRNA destabilization, moreover a greater repression was observed when
the miRNA-binding sites were close each other (Grimson et al., 2007).
3) miRNA binding sites are fully functional only in their endogenous positions within
the targeted UTR, and mutations of the flanking regions also impair miRNA
functions suggesting that they could represent protein binding sites or provide an
appropriate structural context (Didiano & Hobert, 2008). Moreover AU-rich
nucleotide composition immediately flanking the miRNA binding sites, increases
their efficacy as functional site (Grimson et al., 2007).
Figure 6. Characteristics of miRNA/mRNA pairing. Pairing scheme, of a
productive 3’ pairing by imperfect complementarity between the miRNA and 3’UTR.
Perfect pairing between the  2-7nt  seed sequence (purple) of the miRNA and the
complementary sequence of the  target 3’UTR (blue) is necessary for a productive
interaction. Moreover, supplemental pairing to nucleotides 13-16 (orange) of the miRNA
increases the binding affinity. The bulge presents in the central region of the miRNA-
mRNA duplex precludes the Ago2-mediated endonucleolytic cleavage of the mRNA. From:
(Grimson et al., 2007).
miRNA/mRNA binding features also determine the fate of the target mRNA. Indeed,
perfect miRNA/mRNA pairing preferentially induces target mRNA cleavage, as is the case
of most plant miRNAs, whereas partial miRNA/mRNA complementarity (depicted in
Fig.6), observed in the majority of animal miRNAs, can lead to both translational
repression or accelerated decay of the target mRNA (Kiriakidou et al., 2007).
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Indeed, numerous studies, often coming to divergent results, have provided experimental
evidences that miRNAs can either repress translation of endogenous mRNAs or artificial
reporters, without affecting the target mRNA levels (Mathonnet et al., 2007), or induce
deadenylation and subsequent decay of target mRNAs (Eulalio et al., 2009; Wu et al.,
2006).
The translational inhibition was reported to occur to either the initiation or post-initiation
step, or even both, depending on the miRNA, the cellular context and the experimental
procedures employed (see Fig.7).
One proposed mechanism by which miRNAs can inhibit initiation of translation relies on
the capacity of Ago2 protein to bind the 7-methyl cap (m7G cap) to the target mRNAs 5’
end (Kiriakidou et al., 2007). Thus, Ago2 can displace the translational initiation complex
from the binding of the m7G cap and interferes with the initiation of translation. Several
other experimental evidences support such mechanism of action. Indeed, cap-independent
translation of reporter mRNAs bearing internal ribosome entry site (IRES) elements failed
to be repressed in several reports, and in cell free systems the m7G-cap was required for
miRNA repression (Humphreys et al., 2005; Mathonnet et al., 2007; Wakiyama et al.,
2007). In other studies miRNAs functions required also an intact poly(A) tail and
translational repression only occurred when target mRNAs contained both an m7G cap and
the poly(A) tail (Wakiyama et al., 2007). Other studies, in Hek293 cell extracts, showed
that mRNAs containing miRNA-binding sites underwent deadenilation irrespective of
whether they contained an m7G cap or IRES sequences.
miRNA-mediated deadenilation might then decrease the stability of mRNAs and inhibit
translation by disrupting the mRNA circularization, which is required to increase
translation efficiency (Eulalio et al., 2009; Wakiyama et al., 2007; Wu et al., 2006).
Other studies have proposed additional mechanisms of translation inhibition, by which the
miRNA-RISC complex can physically interfere with either the ribosomal subunits
recruitment to the target mRNA or the translation elongation process, rendering ribosomes
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prone to premature termination of translation (see Fig.7) (Lytle et al., 2007; Wu L and
Belasco, 2008). Possible cotraslational degradation of nascent peptides induced by
miRNAs has been also proposed, however the involved protease enzyme is yet to be
identified. The proposed miRNA mechanisms of action are depicted in Fig.7.
Significant fractions of miRNA-repressed mRNAs are found concentrated in cytoplasmic
foci known as p-bodies (processing bodies). P-bodies are dynamic aggregates of RNA and
proteins containing high concentrations of miRNAs and RISC-associated proteins (Ago 1-
4, GW182, etc.) but lack ribosomes and all translation initiation factors, with the exception
of eIF4E (Pillai et al., 2007). However, whether the P-bodies actively contributes to the
translational inhibition mediated by miRNAs is still unclear (Wu & Belasco, 2008).
Of note, Vasudevan and colleagues have recently shown that miRNAs are able to stimulate
the translation of target genes during cell cycle arrest conditions (Vasudevan & Steitz,
2007; Vasudevan et al., 2007). This effect involves the recruitment of the RNA binding
protein FXR1 to the miRNA-Ago complex. However the mechanisms by which miRNAs
enhance translation, and who are the other players of this intriguing function remains still
unknown.
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Figure 7. Proposed mechanisms of translational repression by miRNAs. (A)
mRNA undergoing translation in the absence of a bound miRNA. Black square, m7G cap;
amber cylinder, protein-coding region; and AAAAAA, poly (A) tail. Ribosomes are colored
green, nascent polypeptides are brown, and the eIF4E subunit of the cap-binding complex
is violet. (B) Inhibition of translation initiation by competition between RISC and eIF4E
for cap binding. RISC is depicted as a ribonucleoprotein complex comprising a miRNA
(red), Ago (pink), and other protein subunits. (C) Inhibition of translation initiation at a
step after cap recognition, such as by impeding the association of the small and large
ribosomal subunits. (D) Inhibition of translation elongation coupled to premature




Although computational approaches have identified almost one thousand of miRNAs
mapping everywhere within the human genome, only a few of them have been
experimentally validated and functionally characterized (Pillai et al., 2007).
Bioinformatics analyses indicate that more than 30% of protein–coding genes may be
targeted by miRNAs, and each miRNA can recognize dozens of targets (Lewis et al.,
2005). Hence, not surprisingly, several reports indicate that miRNAs are involved in
virtually every biological process, including proliferation, differentiation and apoptosis
(Miska, 2005).
Indeed, loss of Dicer leads to lethality early in embryogenesis, with dicer-null embryos
depleted of stem cells (Bernstein et al., 2003) and knock out mice, with loss of the cluster
miR17-92 die shortly after birth, showing lung hypoplasia and ventricular septal defects
(Ventura et al., 2008).
Interestingly, more than 50% of miRNA genes are located in cancer-associated genomic
regions or in fragile sites (Calin et al., 2004) and mutations and miss-expression of
miRNAs have been correlated to various tumors (Calin & Croce, 2006).
To date, several lines of evidences indicate that miRNAs are directly involved in the
tumorigenesis of many cancers.
For example, Dr  Takamizawa and colleagues observed that the expression levels of the
miRNA let-7 were frequently reduced in lung cancers and that reduced expression of let-7
significantly associated with shortened postoperative survival (Takamizawa et al., 2004).
Moreover they reported that over-expression of let-7 in lung cancer cell lines inhibited
tumor cell growth.
As the let-7 gene, several other miRNAs have been classified as oncogenes or
oncosuppressors according to their functions in cellular trasformation. Hence, miRNAs
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have been proposed as potential tools for diagnosis, prognosis and therapy of many cancers
(Zhang et al., 2007).
The molecular mechanisms by which miRNAs can regulate tumorigenesis are unclear. One
possible mechanism is that miRNAs regulate cancer pathogenesis by targeting oncogenes
and/or oncosuppressor genes. We recently provided evidences that support this mechanism
in the MB tumors. Indeed, we have recently shown that miR199b-5p, through direct
targeting of Hes1 gene, key effector of the Notch pathway, exerts onco-suppressor
functions in MB cells. We reported that over-expression of miR199b-5p impairs
proliferation of different MB cells and affects survival of the MB stem-cell subpopulation
(Garzia et al., 2009).
Ferretti and colleagues, also reported oncosuppressor effects mediated by miRNAs in MB
cells, showing that miR125b, miR324-5p and miR326 inhibit cell growth by targeting Smo
or Gli1 gene, two crucial effectors of the Shh pathway (Ferretti et al., 2008).
Although the biological functions of miRNAs in the MB tumor context have been just




miR34 is an evolutionary conserved family of miRNAs consisting of three members in
vertebrates (miR34a, miR34b and miR34c), and one orthologue in invertebrates species.
In human, miR34a precursor sequence maps within the second exon of a EST (expressed
sequence tag) within the chromosome 1p36.23; on the other hand, miR34b and miR34c are
located within the intron 1 and exon 2, respectively, of the same EST within the
chromosome 11q23.1.
Several groups have recently reported that the three miR34 family members are direct
targets of p53 transcription factor (He et al., 2007; Corney et al., 2007; Bommer et al.,
2007); in particular, miRNA expression profiles of five different studies reported miR34a
as the most significantly induced miRNA after activation of p53 (Chang et al., 2007; He et
al., 2007; Raver-Shapira et al., 2007; Tarasov et al., 2007; Tazawa et al., 2007).
p53 binding sites were identified 30Kb upstream of the mature miR34a and 3kb upstream
of the cluster miR34b/c (Corney et al., 2007; Raver-Shapira et al., 2007), and chromatin
immunoprecipitation analyses confirmed the p53 binding (Bommer et al., 2007; He et al.,
2007; Raver-Shapira et al., 2007; Tarasov et al., 2007).
Interestingly, ectopic expression of miR34a recapitulated p53 mediated effects including
cell cycle arrest (Bommer et al., 2007; He et al., 2007; Raver-Shapira et al., 2007; Tarasov
et al., 2007) and induction of apoptosis (Chang et al., 2007; Raver-Shapira et al., 2007;
Tarasov et al., 2007; Welch et al., 2007) and senescence-like phenotype (He et al., 2007;
Tarasov et al., 2007). Remarkably, inhibition of miR34a functions via miR34a-specific
LNA (locked nucleotide analogs) impaired p53-induced apoptosis, upon DNA damage
induction (Raver-Shapira et al., 2007). Therefore, miR34a can be, in some cases, not only
sufficient but also required for mediation of tumor suppression by p53.
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Of note Dr Dutta and colleagues showed that miR34a-mediated effects can be cell-type
dependent, since it also supports cell proliferation of HeLa and MCF-7 cells (Dutta et al.,
2007).
To date, several miR34a targets have been experimentally validated, including CDK4/6,
cyclin E2, cyclin D1, E2F5, MET, Bcl2, MYCN and SIRT1 (Bommer et al., 2007; He et
al., 2007; Sun et al., 2008; Tazawa et al., 2007; Wei et al., 2008; Yamakuchi et al., 2008).
Interestingly, SIRT1 gene (silent information regulator 1) inactivates p53 by deacetylating
it (Yamakuchi et al., 2008), thereby generating a positive feedback loop in which p53
regulates miR34a, which through SIRT1, increases p53 activity. In agreement with this
observation, two different research groups reported that miR34a induction of apoptosis
observed in p53-wt HCT116 cells was strongly attenuated in p53-knock out HCT116 cells
(Chang et al., 2007; Yamakuchi et al., 2008).
miR34a expression was reported significantly downregulated in several human cancers,
and aberrant CpG methylation of its promoter was observed in prostate carcinomas and
primary melanomas, as well as in several tumor cell lines, including lung, breast and colon
carcinoma cell lines (Lodygin et al., 2008).
The high similarity among the three processed miR34 family members suggested that they
may have the same targets. Indeed, after separate transfection of miR34a, miR34b and
miR34c the affected mRNAs were almost identical (He et al., 2007) and although most of
the functional studies focused on oncosuppressor activities of miR34a, the ectopic
expression of miR34b and miR34c was also reported to induce cell cycle arrest and
cellular senescence-like phenotype in tumor cell lines (He et al., 2007). miR34b was also
found silenced by hypermethilation of its promoter in oral squamous cell carcinomas
(Kozaki et al., 2008). However, miR34a and the cluster miR34b/c have distinct tissue-
specific expression patterns, with miR34a presents at highest levels in the mouse brain, and
low or moderate levels in other tissues, whereas miR34b and miR34c most highly
expressed in lung (Bommer et al., 2007).
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In particular, in situ hybridization analysis of rat organs showed the highest expression of
miR34a within the cerebellum cortex, thus suggesting potential biologic roles of the




The miR34a sequence was HindIII/XhoI cloned into a pCDNA3 vector. The seed mutant
was made by site-directed mutagenesis, using the pfu enzyme according to manufacturer
protocol (Roche). The GGC sequence at the seed positions 2-4 of miR34a was replaced
with AAA.
The 620 nt genomic region consisting of miR34b and miR34c precursor sequences and
about 400 nt of spacing genomic region, was HindIII/XhoI cloned in pCDNA3 vector. The
seed mutants were made as for miR34a.
The full-length 3’-UTR of target genes were Not1-cloned into a pRL-CMV vector
(PROMEGA) downstream of the Renilla luciferase coding sequence. The mutant of
DLL1-3’UTR reporter construct was generated by site-directed mutagenesis as above. The
TGCC sequence within the three miR34a-binding sites was replaced with AAAA. The
oligonucleotides sequences of primers pairs employed for vector cloning are shown in
table 2. All of the vectors produced were sequence verified.
The CSL transcription factor reporter construct and the NICD1 expressing vector were a
kind gift of Prof. Nicola Zambrano, University Federico II, Naples. Murine DLL1
expressing construct was a kind gift of Dr Shigeru Chiba department of Cell Therapy and
Transplantation Medicine University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo
113-8655, Japan.
A pool of three Sh-RNA expressing constructs targeting DLL1 was used in our
transfections (clones ID: V2HS_56928; V2HS_56927; V2HS_56930) (Openbiosystems,














miR34b/c prHind S AAAAAAGCTTGTGCTCGGTTTGTAGGCAG







3’UTR DLL1 Mut site1S GGCCGCCTGCGGCACAAAATTCCGTGACGTCGC
3’UTR DLL1 Mut site 1AS GCGACGTCACGGAATTTTGTGCCGCAGGCGGCC
3’UTR DLL1 Mut site 2S ATAAGAAGCATGCACAAAATGAGTGTATATTTTG
3’UTR DLL1 Mut site 2AS CAAAATATACACTCATTTTGTGCATGCTTCTTAT
3’UTR DLL1 Mut site 3S TAGAAACACAAACACAAAATTTATTGTCCTTTTT
3’UTR DLL1 Mut site 3AS AAAAAGGACAATAAATTTTGTGTTTGTGTTTCTA
Table 2. Oligonucleotides developed as primer-pairs used for cloning.
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Daoy and D283-MED medulloblastoma cells were maintained in Eagle’s Minimum
Essential Medium (Eagle’s MEM, Sigma Aldrich, Milan, Italy); ONS76 medulloblastoma
cells were cultured in RPMI medium; SH-SY5Y, SK-N-BE, and GIMEN neuroblastoma
cells, and MCF7 and MDA 231 human breast cancer cells were maintained in DMEM
medium (Sigma Aldrich, Milan, Italy). All media were supplemented with 10% fetal
bovine serum (Celbio Pero, Milan, Italy), 10 U/ml penicillin and 0.1 mg/ml streptomycin
(Celbio Pero, Milan, Italy).
Stable clone selection
Daoy cells were transfected by using TransIT-LT1 reagent (Mirus) according to
manufacturer instructions. Briefly, cells were plated in 10 cm dish plates at a 60%
confluence. The following day, the cell culture medium was replaced 16 ml of complete
growth medium and a mix of 45ul TransIT-LT1 reagent and 15ug of DNA were added to
the cells. Upon 48 h cells were maintained in a complete growth medium containing 0.3
µg/ml neomycin (GIBCO). Following almost three weeks single clones (clone#1 and #2)
and one mixed clone (clone#3) were selected.
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Luciferase assays
In luciferase assays performed in Daoy, SH-Sy5y, SK-N-BE and GIMEN cells, cells were
transfected with the indicated reporter constructs and miR34a or seed mutated miR34a
expressing vectors or empty vector, by using TransIT-LT1 reagent (Mirus) according to
manufacturer instructions. The pGL3 control vector (PROMEGA) was used for
transfection normalization. Experiments were performed in triplicate in 96-well plates, and
luciferase assays were carried out following 24 h of transfection using the Dual-luciferase
Reporter assay system (PROMEGA), according to manufacturer procedures.
For luciferase assays performed HEK293 cells, DNA vector transfectios were performed
using CaCl2 and Na2PO4 reagents. The pGL3 control vector (PROMEGA) was used for
transfection normalization. Experiments were performed in triplicate in 96-well plates, and
luciferase assays were carried out following 24 h of transfection using the Dual-luciferase
Reporter assay system (PROMEGA), according to manufacturer procedures.
Time-course experiments
Two different transfections were performed in 6-well-plated Daoy and D283-MED cells to
obtain the following time points: first transfection, from 6 h to 14 h; second transfection,
from 16 h to 20 h. The cells were transfected at a 80% confluence by using TransIT-LT1
reagent (Mirus) using 7 µl of reagent and 2.5 µg of DNA per well. At each time point, the
cells were harvested and lysated using RIPA buffer or TRIZOL reagent, according to
manufacturer instructions. For western blotting the following antibodies were used: Delta1
(H-265) sc-9102 (Santa Cruz) (≈77 kDa); activated Notch2 (ab8926) (Abcam) (≈82 kDa);
Notch1 (ab52627) (Abcam) (≈120 kDa); Hes1 (kind gift of Dr.Tetsuo Sudo, TORAY
Industries, Tebiro Kamakura, Japan) (≈35 kDa); ANTI-β-actin (A5441) (SIGMA).
Of note, in the Daoy cell time-course experiments, the DLL1 protein was detected as a
clear band of ≈77 kDa (predicted molecular mass), however a band of ≈95 kDa was also
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observed when more then 30 µg total lysate was loaded (western blotting of the stable
clones). The two bands were both down-regulated by miRNA34a. In D283-MED cells,
DLL1 was detected as two clear bands: 77 kDa and 160 kDa, on the same films. Each band
was down-regulated at the same rate at the 10h time point.
RT-PCR and real-time PCR detection
Total RNA was extracted and 2 µg were retro-transcribed using the ISCRIPT enzyme
(BIORAD), according to manufacturer protocol. Total RNA was extracted from cerebellar
controls or tumoral specimens by homogenizing the samples within TRIZOL reagent
according manufacturer instructions. RNA was then retro-transcribed as above. Syber-
green real-time PCR was performed using standard protocols, with an Applied Biosystems
(Foster city, CA) 7900-HT FAST real-time PCR sequence detection system, as described
previously (Bulfone et al. 2005). Experiments were performed in duplicate, and human sn-
U6 RNA or GAPDH and β-ACTIN were used as references for miR34s or mRNA
expression, respectively. The primers were generated by using the Primer Express
program, acquired from Applied Biosystems.
MTS cell proliferation assay
For stable clones, viable cells (2,000) were plated in 96-well plates and left over-night.
MTS proliferation assay was then performed by using the CellTiter 96R AQueous One
Solution Reagent Non-Radioactive Cell Proliferation Assay (PROMEGA), according to
manufacturer procedure. Breafly, upon the indicated time points cell culture medium was
replaced with a tetrazolium compound containing complete growth mediun. Upon two
hours absorbance at 490nm was measured by using EnVision 2102 multilable reader
instrument (PerkinElmer, Waltham, Massachusetts 02451, USA).
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For transiently transfected cells, six well-plated cells were transfected as previously
described. Upon 24 hours from transfection 2000 viable cells were plated in 96-well plates.
MTS was performed as above.
Apoptosis Analysis.
For FACS analysis, 500.000 viable cells of miR34a Daoy stable clones and the empty
vector clone were harvested and stained with propidium iodide and anti-Annexin-V
antibody. Cells were, subsequently, analyzed by using the FACS Calibur instrument
(Becton Dickinson, San Jose CA).
D283-MED and ONS-76 cells plated in 96-well plates were transfected using the TransIT-
LT1 reagent (Mirus). After the indicated time, the cells were lysated by adding to the
growth medium equal amount of lysis buffer 2X (60 mM Tris, pH 7, 300 mM NaCl, 2%
Triton X 100, 2% glycerol). Ten µl lysate was incubated for 1 h at 37 °C in the dark in 96-
well plates (CORNING) with 90 µl reaction mix: 10 µl reaction buffer (20 mM Hepes, 10
mM NaCl, 1 mM EDTA, 0.1% CHAPS), 50 µl 20% sucrose, 1 µl 1 M DTT, 0.2 µl
fluorigenic caspase 3/7 substrate, 20 mM Ac-DEVD-AFC (BIOMOL), made up to 90 µl
with water. After a 1-h incubation in the dark, fluorescence emission at 505nm was
detected by using EnVision 2102 multilable reader instrument (PerkinElmer, Waltham,
Massachusetts 02451, USA)., at 505 nm emission..
2’-0-Methyl antisense experiments
miR34a-2-0-Methyl antisense is a chemically synthesized, single-stranded, modified RNA
which specifically inhibits endogenous miR34a functions after transfection into cells
(http://www1.qiagen.com/Products/miScriptmiRNAInhibitors.aspx) (product name: Anti-
has-miR-34a ) (QIAGEN S.p.A. Via Grosio, 10/10, 20151 Milano).  Unrelated-2-O-methyl
41
antisense was synthesized and chemically modified by Prof Aldo Galeone, University of
Naples and Biological Science faculty, Italy.
Oligos were transfected at a final concentration of 80 nM by using TransIT-LT1 reagent
(Mirus) according to manufacturer instructions in 96 well or 6 well-plated Daoy cells, for
caspase assays or western blots analyses, respectively. Following 8 hours from transfection
cell culture medium was replaced with fresh or doxorubicin containing medium (final
concentration 0.2ug/ml). Upon 12 hours caspase 3/7 or western blotting assay was
performed as described above.
Soft agar colony formation assay.
D283-MED and ONS-76 cells were transfected with miR34a expressing vector or empty
control vector. Following 24 hours 10.000 cells were plated in the appropriate medium in
0.35% agar over a 0.5% agar base. Three plates were plated for each transfection (miR34a
and empty vector) or untrasfected cells. Medium was replaced every week.  Following
eight weeks colonies were counted.
Patient tumor source.
Control human tissues were obtained from the NICHD Brain and Tissue Bank for
Developmental Disorders, at the University of Maryland, Baltimore, Maryland, USA (see
Table 3).
Surgical MB specimens were from the Department of Neurosurgery,
Santobono/Pausillipon Hospital, Naples, Italy. All of the specimens were obtained at the
time of diagnosis, prior to radiation therapy or chemotherapy, and they were subjected to
histopathological review according to the WHO criteria (see Table 4).
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RNA was extracted from tissue samples as described above. Syber green Real Time PCR
was performed as described above. The two-tailed Mann-Whitney test was used for p-
values calculations.
Table 3. Additional data of control samples. List of control samples analysed by
using real-time RT-PCR detection assay for evaluation of miR34a expression. The final
column presents the means of the miR34a, miR34b and miR34c C-t values normalized for
sn-U6 RNA C-t values
.
Table 4. Additional data of patient tumor samples. List of the MB patients from
whom the samples were surgically removed and then analyzed be using a real-time RT-
PCR detection assay for the evaluation of miRNAs expression. The final column presents
the means of the miR34a, miR34b and miR34c C-t values normalized for sn-U6 RNA C-t
values.
Adenovirus infections.
6-well plated 200.000 SH-Sy5y cells were infected with mock or miR34a-expressing
adenoviruses at a final title of 200 MOI. 24h following infection the medium was replaced
with virus-free medium. 72h upon infection cells were harvested and western blot was
performed, as described above. Adenovirus particles were purchased by the ViraQuest,
Inc. North Liberty, IA 52317.
Age at diagnosis Follow-up Histology M stage 
patient Gender (months) (months) (OMS 2000) (Chang) note DDct miR34a DDct miR34b DDct miR34c
MB1 F 35 1 large cell M3 dead from disease 0.000439562 0.000164754 0.00000092
MB2 F 89.75 34 classic M0 alive 4.03733E-05 2.18233E-05 1.77896E-05
MB3 F 26 24 desmoplastic M0 alive 0.000187749 4.7404E-05 0.0000026
MB4 F 123.75 6 classic M0 alive 0.000150429 7.873E-05 5.12863E-05
MB5 F 64.25 18 classic M0 dead from disease 1.90E-09 0.000232943 1.26785E-05
MB6 M 76.25 17 classic M0 alive 1.02598E-05 0.000140319 7.31007E-06
MB7 M 68.5 36 desmoplastic M2 alive 0.000132799 0.000576276 0.0000033
MB8 F 168.5 15 classic M0 alive 4.94992E-05 5.61323E-05 1.1765E-05
MB9 M 127.5 10 anaplastic M0 alive 0.000172207 9.55637E-05 0.0000061
MB10 M 29 4 classic M0 alive 0.000814396 0.00142609 0.0000064
  Age of Death 
Sample Geneder Origins years days Cause of Death DDctmiR34a DDctmiR34b DDctmiR34c
C1 M African American 0 5 Congenital Heart Defect 0.0003485 0.005645265 0.007459893
C2 M Caucasian 0 96 Bronchopneumonia 0.0001471 0.000546491 0.000624322
C3 M African American 1 123 Dehydration 0.0006622 0.00082695 0.000911772
C4 M Caucasian 0 119 Bronchopneumonia, Acute 0.0014122 0.00063039 0.000829206
C5 F Caucasian 0 20 Pneumonia 0.0005040 0.000816189 0.000984741
C6 M Caucasian 4 258 Drowing 0.0077462 0.005678301 0.006293369
C7 M African American 0 68 Asphyxia 0.0032145 0.003607516 0.004983445
C8 F African American 0 62 Pneumonia 0.0011743 0.000618703 0.001002884
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RESULTS
By computational analyses we noticed that several miR34a predicted targets
are key genes of the Notch and Shh signaling: DLL1 (Delta-like protein 1) and
Jag1, and Notch1 and Notch2, two ligands and two receptors of the Notch pathway,
respectively, and Gli1, a key effector of the Shh pathway (Table 5).
miRanda TargetScan PicTar PITA
DLL1 18.13 90 14.53 -13.98
JAG1 ---- 77 4.82 -12.78
NOTCH1 ---- 95 9.64 -14.37
NOTCH2 ---- 68 5.17  -9.93
GLI1 16.15 ---- ----   2.05
      * MET 16.82 88 8.56  -8.16
      * BCL2 ---- 86 1.34 -14.23
Table 5. Selected miR34a targets. m iR34a targets were selected by
examining the target definitions of the indicated miRNA databases. Each database
relies on different algorithms of target prediction and uses different read-out
scales. For example PITA algorithm shows ΔΔG energetic values of the predicted
miRNA/mRNA binding. Therefore the more negative is the value, the stronger the
binding of the miRNA to the given site is expected. More then one miR34a-binding
site is predicted for the DLL1, Notch1 and Jag1 3’UTRs (see also Fig. 8). In those
cases the numbers given in Table 5 represent the score of the binding site with the
best match for miR34a binding. If a database does not predict a selected gene as a
miR34a target, the correspondent field is marked with the symbol “----“. *= MET
and BCL2 genes were chosen from among the experimentally validated miR34a
targets as references for the scores values (Bommer et al., 2007; He et al., 2007).
Given the crucial roles of these pathways in the MB context, we
investigated whether miR34a could really target the selected genes and whether the
miR34a expression has functional consequences in MB cells.
To evaluate whether miR34a effectively recognizes the 3’UTR of the
selected genes in MB cells, we cloned the 3’-UTR full-length sequences
downstream of a luciferase open reading frame (ORF) and the miR34a precursor
sequence into a pCDNA3 vector.
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As shown in Figure 8, transfection of miR34a expressing vector
significantly down-regulated DLL1 reporter activity in Daoy cells, whereas no
significant inhibition was observed on the Jag1, Gli1, Notch1 and Notch2 reporters.
Moreover, mutations of the three miR34a binding sites within the DLL1 3’UTR
completely abrogated the inhibitory effect of miR34a (Fig.9). These results
indicated that miR34a directly targets DLL1-3’UTR in MB cells, by recognizing
the predicted binding sites.
Figure 8. Direct recognition and validation of miR34a target genes
using luciferase assays. Daoy cells were co-transfected with 3’UTR reporter
constructs, pGL3 control vector and empty vector, miR34a or seed-mutated
miR34a. Representative 3’UTR pictures above columns show the number of
miR34a binding sites predicted in each 3’UTR. Experiments were carried out in
triplicate and the means are shown as percentages relative to the empty vector.
Two-tailed upaired t-test was used for statistical analyses and p-values were
calculated comparing the luciferase values of the empty vector- and the miR34a-
transfected sample. Luciferase assays were performed following 24h from
transfection.
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Figure 9. Luciferase assay of mutated DLL1 3-UTR reporter vector.
Daoy cells were cotransfected with mutated DLL1-3’UTR construct, pGL3 control
vector and empty vector, miR34a or seed-mutated miR34a. Experiments were
carried out in triplicate and the means are shown as percentages relative to the
empty vector. Luciferase assays were performed following 24h from transfection.
The mutated reporter construct was generated as described in material and
methods.
We subsequently investigated whether miR34a can affect the endogenous
expression of DLL1. Furthermore, since DLL1 is a known ligand of Notch1 and
Notch2 receptors (Shimizu et al., 2000a; Shimizu et al., 2000b), we evaluated the
possibility that miR34a expression can influence both pathways.
In-vitro studies have shown that miRNAs can induce translational inhibition
in a time frame of even less than 1 h (Mathonnet et al., 2007), and in vivo studies, in
cells, have indicated a down-regulation of target genes from 8 h following miRNA
transfection (Wang, 2006). Therefore, we investigated time courses in Daoy cells
starting from 6 h from miR34a transfection, while also transfecting duplicates at
each time point for protein and RNA analyses.
As shown in Figure 10, miR34a expression, evaluated at each time point
(see Figure 11), resulted in a transient reduction in DLL1 protein levels by 8 h, and
then at 18 h from transfection. At these time points no decrease in DLL1 mRNA
levels was detected (Fig.12), suggesting potential effect of miR34a on DLL1
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translation. On the other hand, the recovery of DLL1 protein levels at the 12 h time
point was supported by a transitory increase in its mRNA levels (Fig.12), which
could be due to inherent feedback mechanisms of the Notch pathway, as previously
described by Dr Shimojo and colleagues (Shimojo et al., 2008).
Figure 10. Time courses of miR34a over-expression in MB Daoy cells.
Western blotting of transient expression of miR34a in Daoy cells at different times
post-transfection, using an antibodies panel for detection of the endogenous
proteins: DLL1, Nicd1, Nicd2 and Hes1. The procedure used was as described in
materials and methods.
Figure 11. miR34a ectopic expression by real-time RT-PCR detection.
miR34a expression analysis, by real-time PCR assay, reveals miR34a over-
expression at each time point from 6 h after transfection of Daoy cells. miR34a
values were normalized according to sn-U6 RNA expression levels, and  fold of
expression compared to miR34a endogenous expression in Daoy cells are shown.
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Figure 12. DLL1 expression analysis, upon transfection of miR34a, by
real-time RT-PCR detection. Real-time PCR analysis of DLL1 mRNA expression
was performed from RNAs extracted by Daoy cells, at the indicated time points
upon miR34a transfection.  DLL1 values were normalized according to GAPDH
expression. Experiments were performed in duplicates and averages of 2^-Dct values
are shown.
The down-regulation of DLL1 was followed by rapid Notch1 activation, as
determined by Notch1 intracellular domain (NICD1) protein detection (Fig.10).
The activation of downstream signaling was also confirmed by the expression
induction of the CSL transcription factor-reporter construct, detected at 14 h from
miR34a transfection of Daoy cells (Fig.13).
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Figure 13. CSL transcription factor reporter assay by using protein
lysates of miR34a transfected Daoy cells. A. Daoy cells were co-transfected with
CSL luciferase reporter construct, pRL-CMV vector and empty vector, mutated
miR34a, wild type miR34a. (B) We transfected a NICD1 expressing vector as
positive control for CSL reporter construct. Luciferase assays were performed
following 14 hours from transfection, firefly luciferase values were normalized with
renilla luciferase values, and averages of triplicates are shown. Two-tailed
unpaired t-test was used for statistical analyses.
The miR34a over-expression also resulted in a transient inhibition of
Notch2 signaling, as seen by NICD2 and Hes1 protein down-regulation (Fig.10). A
reduction in Hes1 mRNA confirmed the inhibition of the upstream pathway
(Fig.14).
Figure 14. Hes1 endogenous expression analysis by real time RT-PCR
detection, of Daoy cells after transfection of miR34a expressing vector. Real-
time PCR analysis was performed, by using Hes1specific primers, upon miR34a
transfection in Daoy cells.  Hes1 values were normalized according to GAPDH
mRNA expression.
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Notch1 activation and Notch2 inhibition are not likely to be results of gene
expression variations, since the mRNA levels did not follow the same trends in
endogenous expression (Fig.15A and Fig.15B).
Figure 15. Notch1 and Notch2 endogenous expression upon miR34a
transfection. A. Real-time PCR analysis was performed, by using Notch1 or
Notch2 (B) specific primers, upon miR34a transfection in Daoy cells.  Notch1 and
Notch2 values were normalized according to GAPDH mRNA levels of expression.
Consistently with luciferase assays results reported in figure 8, transfection
of the seed mutated miR34a, as negative control experiment, did not have any
effects on DLL1 protein levels (see Fig.16).
Figure 16. Western blot analyses of miR34a or seed mutated miR34a
transfected Daoy cells. Western blot of Daoy cells at 18 h from transfection of
miR34a or seed-mutated-miR34a using an anti-DLL1 antibody. Non-transfected
Daoy cells were used as control. The densitometric quantification of DLL1 band
normalized with β-actin expression is shown below.
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Time courses were also performed in an other MB cell line (D283-MED),
which showed similar results (Fig.17). In this case, we saw DLL1 protein down-
regulation at 10 h post-transfection, followed by strong Notch1 activation. At the
same time, Notch2 signaling was inhibited and the Hes1 protein was found down-
regulated.
Figure 17. Time courses of miR34a over-expression in MB D283-MED
cells. Western blotting of miR34a-transiently transfected D283-MED cells at
different times post-transfection, using an antibodies panel for detection of the
endogenous proteins: DLL1, Nicd1, Nicd2 and Hes1. The procedure used was
described in materials and methods.
These results indicate that ectopic expression of miR34a in MB cells
transiently down-regulates DLL1 protein levels and also influences the Notch1 and
Notch2 pathways.
Previous studies have demonstrated that the soluble dominant-negative form
of DLL1 inhibits cell proliferation in Daoy and D283-MED cells (Hallahan et al.,
2004), and we also observed inhibition of proliferation of Daoy cells upon
transfection of DLL1-Sh RNA constructs (Fig.18 and Fig.19). Moreover the
Notch1 and Notch2 pathways have shown opposite effects in MB cells: Notch1
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activity inhibited cell growth, whereas Notch2 signaling and Hes1 expression
supported cell proliferation (as already shown by Fan et al., 2004).
Altoghether, these findings suggested that miR34a expression has an anti-
proliferative effect in MB cells.
Figure 18. MTS proliferation assay of Daoy cells upon transfection of
DLL1 sh-RNAs. MTS proliferation assay was performed in Daoy cells at indicated
time points upon transfection of a pool of three different sh-RNA constructs tareting
the DLL1 sequence. Significant impairment of proliferation was detected at 96h
from transfection (*= p-value < 0.04).
Figure 19. Expression levels of DLL1 protein upon DLL1-sh-RNA
transfection in Daoy cells. Western blot analysis was performed in Daoy cells 72h
from transfection of a pool of 3 different sh-RNAs expressing vectors targeting the
DLL1 sequence, or an unrelated- sh RNA by using anti-DLL1 and β-actin
antibodies.
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To investigate the functional effects of miR34a in MB cells, we generated
miR34a stable clones in Daoy cells (Fig.20).
Figure 20. miR34a expression by real-time RT-PCR detection in Daoy
stable clones. miR34a expression in three different stable clones is shown as fold of
expression compared to endogenous miRNA expression in Daoy cells. sn-U6 RNA
was used to normalize themiR34a expression values.
These clones showed a reduction in the DLL1 protein and down-regulation
of NICD2 intracellular levels and Hes1 expression (Fig.21). Of note, activation of
Notch1 was observed only in two out of three clones. We postulate that given the
role of Notch1 in MB cells, survival mechanisms might have been selected to
inhibit Notch1 activation in those cells (see western blot analysis of clone#3).
Figure 21. Western blot analyses of Daoy stable clones. Stable miR34a
clones (clones 1, 2 and 3), one stable empty vector clone and unselected Daoy cells
were subjected to Western blotting using the indicated antibodies panel.
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Nevertheless, the MTS cell proliferation assay and FACS analysis for
Annexin V detection revealed significant impairment of proliferation and a higher
fraction of apoptotic cells in all the miR34a-overexpressing clones, as compared to
the empty vector control clone (Fig.22 and Fig.23). These results were in agreement
with behavior of stable clones in culture, which grew slower than control clones
and wt cells, and then spontaneously died.
Figure 22. MTS proliferation assay of Daoy clones over-expressing
miR34a. MTS proliferation assay performed on stable clones and Daoy cells, as
described in materials and methods. The absorbance means were evaluated from
triplicates under normal serum conditions. *= p-value <0.02 (calculated for
absorbance values of each clone compared with the control clone).
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Figure 23. Apoptosis detection by FACS analyses of miR34a over-
expressing stable clones. Basal apoptosis of stable clones grown under the same
selection conditions was investigated by FACS assay. Percentages of cells in early
and late apoptosis (Q4 and Q2 squares, respectively) are marked with red circles.
The miR34a stable clones also showed a more differentiated phenotype (see
Fig.24), therefore we investigated whether miR34a over-expression was influencing
the cellular differentiation rate.
Figure 24. Morpfological features of miR34a stable clones resemble a
more differentiated phenotype. Morphological phenotype analysis of the miR34a
stable clone#1 and clone #2, compared to a stable clone containing the control
vector, under light microscope (Leika DMIL, 40X 0.22 magnification), showing
extensive neurite out-growth processes and resembling a more differentiated
phenotype.
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As shown in figure 25, we analyzed a panel of expression of differentiation
markers, detecting high levels of the glial marker GFAP (Fig.25). Of note, Daoy
cells have been previously reported to specifically express glial-specific protein
under different conditions, such as induction of differentiation by phenylbutyrate
treatment or epidermal growth factor (EGF) stimulation (Li et al 2004, Shen et al
2001).
Figure 25. Expression analyses of differentiation markers by real time
PCR assay of miR34a Daoy stable clones. Real-time PCR detection of
differentiation markers reveals induction of a glial phenotype, as shown by up-
regulation of GFAP mRNA expression. Experiments were performed in duplcate,
and average of β-actin normalized expression values are shown.
In agreement with the phenotype observed in the Daoy stable clones,
transient transfection of miR34a resulted in inhibition of proliferation and induction
of apoptosis in MB ONS-76 and D283-MED cells (Fig.26 and Fig.27).
Interestingly, co-transfection of DLL1 expressing vector rescued the caspase3/7
activation induced by miR34a expression in Daoy cells (Fig.28 and Fig.29).
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Figure 26.  MTS proliferation assay of MB ONS76 and D283-MED cells
upon transfection of miR34a expressing vector. MTS proliferation assay
performed on miR34a or empty vector transiently transfected ONS76 and D283-
MED cells. The absorbance means were evaluated from triplicates under normal
serum conditions. Folds of the means at each time point calculated with the time 0
h are shown. * = p-values were calculated as <0.02 for ONS76 at 48h and 72h time
points  and D283-MED at 72 h time point.
Figure 27. Caspase3/7 assay in ONS76 and D283-MED cells upon
miR34a expression. A. Caspase-3/7 assays were carried out in ONS-76 and D283-
MED (B) at 24 h and 48 h after transfection of miR34a or an empty control vector,
as described in materials and methods. p-values were calculated comparing the
caspase 3/7 activity values of the miR34a transfected samples with empty vector
transfected samples, by using two-tailed unpaired t-test analyses.
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Figure 28. Caspase 3/7 activity upon transfection of miR34a or miR34a
and DLL1. Caspase 3/7 assay was performed 24 hours from co-trasfection of
miR34a and murine DLL1 expressing vector or miR34a and empty vector. Average
and standard deviations of the results of triplicates are shown.
Figure 29. Western blot analysis of Daoy cells upon transfection of
murine DLL1 expressing vector. Western blot analysis was performed 24 hours
from transfection of murine DLL1 expressing vector or empty vector in Daoy cells,
by using DLL1 and β-actin specific antibodies.
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Moreover, in-vitro assays of tumorigenicity also showed a significant
reduction in soft agar colony formation, upon miR34a over-expression, in both
ONS76 and D283-MED cells (Fig. 30).
Figure 30. miR34a expression impairs soft agar colony formation of
D283-MED and ONS76 cells. A. and B. Representative fields of soft agar colony
formation at 8 weeks upon transfection of empty vector or miR34a expressing
vector or untrasfetced D283-MED and ONS-76 cells. C. Colony number average
was calculated from three representative fields of each plate. Three plates for each
sample (untrasfected and empty vector or miR34a transfected) were counted (*= p-
value < 0.001).
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Altogether, these results indicate that miR34a can impair cell proliferation
and in-vitro tumor growth and induce differentiation processes and apoptosis in MB
cells. Furthermore, DLL1 downregulation can contribute to the apoptotic effect
observed in Daoy cells.
In order to evaluate a possible involvement of miR34a in MB
tumorigenesis, we investigated whether it was deregulated in human MB tumors.
We also analysed the expression of the other miR34 family members, miR34b and
miR34c, which share high sequence homology with miR34a. Interestingly, all of
the miR34 family members were down-regulated in ten MB tumors and three MB
cell lines, compared with eight non-tumoral human cerebellum samples (Fig.31).
Figure 31. miR34s expression analyses in human MB tumors. mir34a,
miR34b and miR34c expression analysis by real-time PCR in human MB tumors,
three different MB cell lines and human normal cerebellum samples. p-values were
calculated by using two-tailed Mann-Whitney test. (for patients follow up and
human normal cerebellum features see also Table 3 and 4 in material and
methods).
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To investigate functional effects of the endogenous miR34a in MB cells, we
transfected a miR34a-2’-O-methyl antisense oligoribonucleotide (miR34a-2-O-Me)
to specifically block endogenous miR34a functions, and stimulated Daoy cells with
the genotoxic agent doxorubicin, a p53 and miR34a activator (as previously
described by He et al., 2007). Real-time expression analyses of p21waf1 mRNA
levels (known target of p53 transcription factor) and miR34a endogenous levels,
confirmed the activation of p53 in Daoy cells, upon doxorubicin stimulated (see
Fig.32).
Figure 32. Expression analyses of p21waf1 and miR34a in doxorubicin
stimulated Daoy cells. A. Daoy cells were stimulated with 0.2ug/ml doxorubicin.
Following 12 hours total RNA was extracted and real time PCR analyses was
performed by using p21waf1 or miR34a (B) specific primers. Average of duplicates of
p21waf1 and miR34a expression values are shown.
We then compared the apoptotic effects of doxorubicin stimulation in non-
transfected cells, and Daoy cells transfected with miR34a–2’-O-Me or an unrelated-
2’-O-Me (un-2-O-Me). As shown in Figure 33, transfection of miR34a–2’-O-Me
resulted in attenuation of caspase3/7 activity, thus suggesting that the endogenous
miR34a is involved in the induction of p53-mediated apoptosis in Daoy cells.
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Figure 33. Endogenous miR34a is involved in induction of apoptosis
upon doxorubicin stimulation in Daoy cells. Caspase 3/7 assay upon 12 hours of
doxorubicin stimulation, of non-transfected or previously transfected with
unrelated or miR34a-2-O-methyl antisense oligos Daoy cells. *= p-value < 0.03;
**= p-value 0.05.
Interestingly, despite the increase in DLL1 mRNA levels (Fig. 34),
doxorubicin stimulation resulted in DLL1 protein down-regulation (Fig. 35) and
transfection of miR34a-2’-O-Me partially recovered the DLL1 protein levels
(Fig.35). These results indicate that the endogenous miR34a can regulate the DLL1
protein expression.
Figure 34. Real time PCR analysis of DLL1 gene expression upon
doxorubicin stimulation. Real time PCR expression analysis by using DLL1
specific primers reveals induction of expression upon 12 hours of doxorubicin
stimulation. Average of duplicates experiments normalized with β-Actin expression
values is shown.
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Figure 35. Transfection of miR34a-2’-O-Me partially rescues DLL1
protein levels upon doxorubicin stimulation. Western blotting analysis was
carried out by using anti-DLL1 antibodies, on untreated or doxorubicin stimulated
Daoy cells, untrasfected or 2’-O-Me transfected cells, as indicated in the panel.
The densitometric quantification of DLL1 band normalized with β-actin expression
is shown below.
Time course experiments of doxorubicin stimulated Daoy cells also revealed
a transient down-regulation of DLL1 protein levels (Fig.36), despite the induction
of the mRNA expression, which was observed at each time point (see Fig.37). This
effect was not observed in miR34a-2’-O-Me transfected cells (Fig.36), therefore
further confirming that the induction of the endogenous miR34a, upon p53
activation induces down-regulation of the direct target DLL1. Induction of both
miR34a and p21waf1 mRNA levels were analysed at each time point, and results are
shown in Fig.38.
Of note, doxorubicin stimulation also induced a down-regulation of NICD2
and a late and weak inhibition of Hes1, however no activation of Notch1 was
observed  (Fig.36). NICD2 inhibition was only weakly reverted by miR34a-2’-O-
Me transfection suggesting that the down-regulation of its expression could be
mediated by indirected mechanisms of action induced by doxorubicin treatment. As
further proof, it was observed that p53 activation inhibits Notch processing by
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transcriptionally inhibiting the expression of presenilin, a known component of the
γ-secretase complex (Laws & Osborne, 2004).
Figure 36. Time courses experiments of doxorubicin stimulated Daoy
cells. Western blot analysis of untrasfected or miR34a-2’-O-Me transfected (right
panel) Daoy cells, not stimulated (NS) or stimulated with for doxorubicin for the
indicated time. DLL1, NICD2, Hes1 and β-Actin protein expression was evaluated
with specific antibodies.
Figure 37. Real time PCR analysis of DLL1 gene expression upon
doxorubicin stimulation. Real time PCR expression analysis of doxorubicin
stimulated Daoy cells, reveals induction of DLL1 expression at each time point.
Averages of duplicates experiments normalized with β-Actin expression values are
shown.
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Figure 38. Real-time PCR analyses of endogenous miR34a and p21waf1
expression in doxorubicin-stimulated Daoy cells. Daoy, cells were treated with
doxorubicin at a final concentration of 0.2ug/ml and RNA was extracted at
indicated time points. Real time PCR analysis was performed by using miR34a and
p21waf1 specific primers. Average of duplicates experiments normalized with sn-U6
RNA and β-Actin relative expression values are shown. Fold of induction of
miR34a and p21waf1 shown below the charts represent the ratio with un-stimulated
cells.
Taken together these results indicate that endogenous levels of miR34a can
regulate DLL1 protein expression in MB cells.
Thus, we subsequently investigated whether this process could be
generalized in other cellular contexts. Since miR34a genomic region (chr1p36) is
frequently deleted or rearranged in neuroblastoma tumors, which also show
rearrangements within the miR34b/c genomic region (chr11q23) (Attiyeh et al.,
2005), neuroblastoma cells could represent a useful tool to investigate the effects of
the endogenous expression of miR34 family members on DLL1 protein levels.
Therefore, we stimulated with doxorubicin the neuroblastoma SH-SY5Y cells, in
which a reported deletion of chromosome 11q23 could affect miR34b/c expression
(Kim et al., 2001), and the SK-N-BE and GIMEN cells, carrying deletion of
chromosome 1p36, thus possibly affecting miR34a expression (Thiele CJ et al.,
1998; Schleiermacher et al., 2003).
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By luciferase assays we confirmed that miR34a expression down-regulates
the DLL1-3’UTR reporter activity in the three neuroblastoma cell lines (Fig.39).
Therefore the different cellular contexts do not inhibit the miR34a/DLL1-3’UTR
binding, and miR34a can potentially down-regulate DLL1 in each cell line.
Fig.39. Luciferase assays of DLL1-3’UTR reporter vector in
neuroblastoma cells. SH-Sy5y, SK-N-BE and GIMEN cells were co-transfected
with DLL1-3’UTR reporter vector, pGL3 control vector and empty vector, miR34a
or seed-mutated miR34a. Experiments were carried out in triplicate and the means
are shown as percentages relative to the empty vector. Luciferase assays were
performed following 24h from transfection.
We also stimulated MCF7 and MDA231 human breast cancer cells, in
which wt and mutated p53 was reported, respectively (Gartel et al., 2003).
We stimulated Daoy cells as control and performed all treatments in
duplicates, to allow real time mRNA expression analyses and western blot assays
for protein levels detection.
As shown in Fig. 40, doxorubicin stimulation resulted in induction of
miR34a in Daoy, SH-SY5Y and MCF7 cells, and induction of miR34b and miR34c
in Daoy and SK-N-BE. At a lower rate, we also detected an induction of miR34b
and miR34c expression in doxorubicin stimulated GIMEN cells, whereas MCF7
cells induced the expression of miR34a and miR34b, but not miR34c. As expected,
the expression of any miR34 isoform was induced in treated MDA231 cells.
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Interestingly, although DLL1 mRNA levels increased in all treated cells
(Fig.42), western blot analyses revealed a strong correlation between miR34a
expression and DLL1 protein downregulation (Fig.41).
Indeed, as shown in Fig.41, DLL1 protein levels were markedly down-
regulated in Daoy, SH-SY5Y and MCF7 cells, whereas increased in GIMEN cells.
No effect was observed in MDA231 cells.
Figure 40. miR34a, miR34b and miR34c expression analyses in
different cell lines upon doxorubicin stimulation. miR34a, miR34b and miR34c
expression analyses by RT-PCR of the indicated cell lines untreated or upon 24h of
doxorubicin stimulation. Fold of expression shown above the graphic represent the
ratio between treated and untreated cells, for each miRNA.
Figure 41. Western blot analyses of different cell lines upon doxorubicin
stimulation. Western blot analyses by using DLL1 and β-Actin specific antibodies,
of doxorubicin stimulated or untreated cells.
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Figure 42. Real time PCR analysis of DLL1 gene expression upon
doxorubicin stimulation of different cell lines. Real time PCR analysis reveals
induction of expression of DLL1 in the indicated tumor cell lines upon 24h of
doxorubicin stimulation.
Adenovirus infection may overcome the variability of cell transfection.
Therefore to further validate the direct effect of miR34a expression on DLL1
protein levels, we infected SH-Sy5y cells with an adenovirus type 5 expressing the
precursor miR34a or an empty virus clone. As shown in Fig.43, infection with
miR34a expressing adenovirus markedly downregulated DLL1 protein levels.
Noteworthy, a weak but visible down-regulation of DLL1 protein levels was
also observed in doxorubicin stimulated SK-N-BE cells (Fig.41), in which miR34a
expression was not induced, but miR34b and miR34c reached the highest levels of
induction among the treated cells (see Fig.40). Since the nucleotide sequences of
miR34 isoforms are highly similar, we thus hypothesize that miR34b and miR34c
might also target DLL1.
We cloned the miR34b/c cluster, as it maps within the genome: the two
precursors miRNAs spaced by 400bp of genomic region, and co-transfected this
construct with DLL1-3’UTR reporter vector in HEK293 cells. As shown in Fig.44
miR34b/c expression downregulated the DLL1-3’UTR reporter activity at the same
rate of miR34a (Fig.44).
68
Figure 43. Western blot analysis of SH-Sy5y cells upon infection with
miR34a expressing adenovirus.  Western blot analysis was performed in SH-SY5Y
cells upon 48h from infection with miR34a expressing or mock adenoviruses. DLL1
and β-actin expression were detected by using specific antibodies. The
densitometric quantification of DLL1 band normalized with β-actin expression is
shown below.
Figure 44. miR34b/c expressing vector down-regulates DLL1 3’ UTR
luciferase activity. HEK293 cells were co-transfected with DLL1 3’UTR reporter
construct, pGL3 control vector and empty vector, miR34a or seed-mutated miR34a,
miR34b/c or seed-mutated miR34b/c. Experiments were carried out in triplicate
and the means are shown as percentages relative to the empty vector. Luciferase
assays were performed following 24h from transfection.
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Altogether these results indicate that the miR34a effects of DLL1 down-
regulation observed in MB cells, can be generalized to other cellular context.




By computational analyses we noticed that some miR34a predicted targets
belong to the Notch and Shh pathway (Table 5, page 43), two signaling pathways
required for survival and tumor growth of medulloblastoma cells (Berman et al
2002; Fan et al. 2006).
In this study, we investigated whether miR34a could effectively target these
two pathways and have oncosuppressor activities in MB.
We report here that miR34a targets the Notch-ligand DLL1 by pairing its
specific binding sites within the DLL1-3’UTR (Fig.8 and Fig.9). This effect
translates into a transient down-regulation of DLL1 protein levels, observed upon
either ectopic expression of miR34a (Fig.10; Fig.17; Fig.21) or induction of the
endogenous miRNA (Fig.35; Fig.36). miR34a ectopic expression also resulted in
inhibition of Notch2 signaling and activation of Notch1 receptor, an effect that we
observed in Daoy and D283-MED MB cells (Fig.10; Fig.17; Fig.21).
DLL1 is known to bind Notch1 and Notch2 and activate each of these
pathways in a non-autonomous manner (ligand and receptor expressed by two
neighboring cells) (Ladi et al., 2005). However, the DLL1/Notch1 interaction
within the same cell (a phenomenon known as cell-autonomous association) has
also been shown to inhibit Notch1 signaling (Ladi et al., 2005; Sakamoto et al.,
2002). We thus hypothesize that cell-autonomous association of DLL1/Notch1
would be a mechanism by which Notch1 signaling is maintained under inhibition in
MB cells, given its inhibitory effects on cell proliferation (as already reported by
Fan et al., 2004).
Indeed, in our time-course studies, down-regulation of the DLL1 protein
was quickly followed by a massive NICD1 expression (see Fig.10 and Fig.17).
Moreover, endogenous DLL1 re-expression is then followed by a marked inhibition
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of Notch1 activation (see Fig.10). Such re-expression could result, at least in part,
from Hes1 down-regulation, as it is known that Hes1 inhibits DLL1 expression
(Shimojo et al., 2008). The reduction in the DLL1 protein levels also correlated
with an inhibition of Notch2 signaling that we showed to occur at the same time as
the reduction in DLL1 protein levels (see Fig.10; Fig.17), thus suggesting a role for
DLL1 as an activator of Notch2 signaling. In agreement with this hypothesis the
inhibition of either DLL1 or Notch2 impairs proliferation of MB cells (Hallahan et
al. 04; Fan.X et al; Fig.18).
DLL1 protein down-regulation was also observed upon induction of the
endogenous miR34a, via p53 activation, in Daoy cells; this effect was then reverted
by miR34a-2’-O-Me oligo transfection (Fig.35; Fig.36). Moreover, in time course
experiments, when the endogenous miR34a was induced, we detected a transient
down-regulation of DLL1 (Fig.36), which is consistent with the results obtained
upon ectopic expression of the miRNA (Fig.10).
It was previously shown that the miRNAs inhibitory effects on target genes,
are sensitive to the relative concentrations of the target mRNA and miRNA
(Mathonnet et al 2007).
We believe that the transitory effect on DLL1 down-regulation observed
upon ectopic expression of miR34a could be referable, at least in part, to variations
in DLL1 mRNA levels (Fig.10).
Indeed, an induction of DLL1 mRNA levels at the 12h time point (see
Fig.12) correlated with the increase in DLL1 protein levels (Fig.10). A possible
explanation could be that miR34a requires a time to inhibit translation of de-novo
transcribed DLL1-mRNA; indeed at the 18h time point, DLL1 protein down-
regulation happens again, in spite of its endogenous mRNA levels, which do not
follow the same trend (se Fig.10 and Fig.12).
On the other hand, during doxorubicin stimulation of Daoy cells (Fig.36),
72
DLL1-mRNA levels increased at each time point (Fig.37). However, miR34a
endogenous expression decreased between 6h and 8h time point (Fig.38).
Therefore, in this case, we can hypothesize that the transient effect on DLL1 down-
regulation could be referable to limiting concentrations of the endogenous miR34a.
Of note, in the time course of Fig.36, despite the down-regulation of DLL1
and the expression of the endogenous miR34a, we did not observe the Notch1
activation, and the down-regulation of NICD2 was observed very weakly reverted
by trasfection of miR34a-2’-O-Me (Fig.36). These results appear to be in contrast
with the previous data shown in figure 10, obtained upon ectopic expression of
miR34a (Fig.10). However, they could be explained by the described crosstalk
between p53 and Notch pathway, by which p53 inhibits the Notch processing by
transcriptionally inhibiting presenilin1 expression, a known component of the γ-
secretase complex (Laws & Osborne, 2004). This effect could explain the absence
of Notch1 activation, in doxorubicin-stimulated cells, and the sustained inhibition
of Notch2, even upon re-expression of DLL1 or transfection of the miR34a-2’-O-
Me. Indeed, as shown in Figure 36, the inhibition of the Notch2 was clearly an
early event, thus likely independent by the DLL1 down-regulation, which was then
observed.
Taken together these results suggest a new mechanism by which p53 can
interfere with the Notch pathway, down-regulating DLL1, via miR34a expression.
This mechanism seems not to be restricted to MB cells, since expression of
endogenous miR34a, upon p53 activation, correlates with down-regulation of
DLL1 in different tumor cell lines (Fig.40; Fig.41). Furthermore, a direct effect of
DLL1 down-regulation upon miR34a ectopic expression was also validated in SH-
Sy5y neuroblastoma cells (Fig.43).
Interestingly, we show that the expression of miR34b and miR34c can also
impair DLL1-3’UTR reporter activity (Fig.44), suggesting that the three miR34
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isoforms can sinergically regulate the DLL1 expression.
To evaluate functional effects of miR34a in MB cells, we generated
miR34a-expressing Daoy stable clones, and also transiently over-expressed miR34a
in different MB cell lines.
In these experiments miR34a was able to induce marked functional effects
in MB cells. It impaired proliferation and soft agar colony formation, and induced
apoptosis and differentiation processes (Fig.22-30). Moreover, depletion of miR34a
also slightly impaired p53-induced apoptosis in Daoy cells (Fig.33).
These results suggest that miR34a can be involved in MB tumorigenesis and
that its down-regulation could confer proliferative advantage to the tumor cells,
contributing to the tumor behaviour.
Consistent with this hypothesis, we show that the expression of miR34a as
well as miR34b and miR34c expression is lost in human MB tumors (Fig.31).
Since several miR34a targets, such as Bcl2 and E2F3 (Bommer et al., 2007;
Welch et al., 2007), are also known regulators of apoptosis and cell proliferation,
the functional effects mediated by miR34a are likely to be referable to the down-
regulation of more than  one target. However, reasonably, target recognition of
miRNAs and their down-regulation efficacy, depend on the expression levels of
both, miRNA and target, and can be cellular context-specific (Mathonnet et al
2007).
Here we show that endogenous levels of miR34a regulate DLL1 expression,
and that the exogenous expression of DLL1 can revert the apoptotic effect mediated
by miR34a, in Daoy cells (Fig. 28). These results suggest that DLL1 down-
regulation can significantly support the functional effects mediated by miR34a in
MB cells.
However, we can hypothesize that other targets will contribute in the
induction and support of the biological effects mediated by miR34a in MB cells.
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It is also noteworthy to note that one of the three miR34a-binding sites
within the DLL1 3’UTR is highly conserved throughout the evolution. Since both
the miR34a sequence and the p53 binding sites within the miR34a promoter region
are also highly conserved in different species, it would be interesting to investigate
whether the axis p53-miR34a-DLL1 is conserved in other species.
Indeed, the lack of p53, possibly correlated with lack of miR34a (which also
shows the highest levels of expression in the cerebellar cortex (Dutta et al 2007),
increases the incidence of MB from 15% to 95% in PTC heterozygous mice
(Wetmore et al., 2001). Therefore, investigations of possible effects of the murine
miR34a in MB mouse models, would also allow a deeper understanding of the roles
of miR34a in the tumorigenesis of this cancer.
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